Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04679831
Other study ID # SSC2580/2
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date May 6, 2021
Est. completion date March 30, 2022

Study information

Verified date July 2022
Source Kenya Medical Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Schistosomiasis is classified as among the world's neglected tropical diseases (NTD). Morbidity due to Schistosoma mansoni (S. mansoni) is greatest among school-age children who typically have the highest burden of infection. In 2001, World Health Organization (WHO) passed a resolution for large-scale mass drug administration (MDA) using chemotherapy to deworm vulnerable children through school-based programs. While MDA has significantly contributed to reducing the burden of these infections, several concerns still exist over the large-scale use of chemotherapeutic drugs in deworming. The large population of children and the high frequency of dosage may pose a challenge to the sustainability of these programs. Further, the MDAs exert increasing drug pressure on parasite populations, a circumstance that is likely to favor parasite genotypes that can resist chemotherapy. Additionally, the current school-based MDA does not consider child malnutrition a very common malady in African countries. The greatest shortcoming is that currently approved S. mansoni chemotherapeutic treatment, Praziquantel is not recommended for children under six years of age due to its perceived toxicity. This excludes a highly vulnerable group from treatment. The above has called for alternative management options for S. mansoni among school and pre-school age children. The current study seeks to test the feasibility of the use of a nutritional supplement (Ujiplus®), as a potential deworming strategy against S. mansoni. Ujiplus® is a porridge flour fortified with papaya (Carica papaya) seeds extracts. In a previous study (NCT 027-25255), the product was found to have an effect on soil-transmitted helminths among a group of school children with no serious adverse events. We intend to evaluate the efficacy of Ujiplus® when given through school feeding programs and compare the outcome with praziquantel- the recommended MDA agent for deworming school children. The investigators will design and formulate the Ujiplus®, and test it among children in four primary schools in Mbita, Homabay county, Kenya.


Description:

Background: Schistosomiasis is classified as among the world's neglected tropical diseases (NTD). Morbidity due to Schistosoma mansoni (S.mansoni) is greatest among school-age children who typically have the highest burden of infection. In 2001, World Health Organization (WHO) passed a resolution for large-scale mass drug administration (MDA) using chemotherapy to deworm vulnerable children through school-based programs. While MDA has significantly contributed to reducing the burden of these infections, several concerns still exist over the large-scale use of chemotherapeutic drugs in deworming. The large population of children and the high frequency of dosage may pose a challenge to the sustainability of these programs. Further, the MDAs exert increasing drug pressure on parasite populations, a circumstance that is likely to favor parasite genotypes that can resist chemotherapy. Moreover, chemotherapeutic drugs are not recommended for children under the age of 6 years due to their toxicity, despite the fact that this is the age group most infected with S. mansoni. Additionally, the current school-based MDA does not consider child malnutrition a very common malady in African countries. Based on the above, we have designed a nutritional food supplement, Ujiplus®, with the potential as a homegrown mass drug administration tool against intestinal parasites including S.mansoni. Porridge (Uji) made from corn flour is one of the most prevalent traditional school meal snacks in developing countries. Because of its low cost, and popularity in schools, it has been adopted as a component in school meals, often prepared and given as a snack at break time. To enhance its effect, we have fortified the Uji flour with micronutrients and extracts from papaya (Carica papaya) seeds to form Ujiplus®. Carica papaya seeds have been found in various studies to have an anthelminthic effect with benzyl isothiocyanate (BITC) as the potential active ingredient. In a previous clinical trial, Ujiplus® reduced the Ascaris lumbricoides egg count by 63.9% after the two month period as compared to the albendazole arm, 78.8%. In this study, primary school children (ages 6-8) from four schools in Homabay County Kenya will be randomized into two arms: Children from two schools will receive 300 ml Ujiplus® porridge daily (test school), and the other two schools will receive a similar serving of plain porridge (cornflour and micronutrients only) with Praziquantel. Prior to the randomization, an initial baseline stool microscopy analysis will be done to determine the presence and intensity of intestinal worms. Core indicators of nutrition-height, weight, and hemoglobin counts-will also be assessed. The children will be monitored daily for three months and final stool sample analysis and clinical monitoring done at the end of the study. Baseline and follow-up data will be collected through Redcap software (Vanderbilt, Nashville, Tenn) analyzed and compared through the latest software of SAS statistical package.


Recruitment information / eligibility

Status Completed
Enrollment 400
Est. completion date March 30, 2022
Est. primary completion date March 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Years to 8 Years
Eligibility Inclusion Criteria: - Consenting parents and guardians Exclusion Criteria: - Children with known allergy to papaya fruit products

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Ujiplus®
Ujiplus® flour, a nutritional supplement will be used to prepare porridge, and each child will be given a serving of 300 ml every school day for 90 days.
Drug:
Praziquantel 400mg
400mg of Praziquantel will be given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300 ml per every school day for 90 days,

Locations

Country Name City State
Kenya Mbita Mbita

Sponsors (2)

Lead Sponsor Collaborator
Kenya Medical Research Institute Kanazawa University

Country where clinical trial is conducted

Kenya, 

References & Publications (5)

Ávila S, Kugo M, Silveira Hornung P, Apea-Bah FB, Songok EM, Beta T. Carica papaya seed enhances phytochemicals and functional properties in cornmeal porridges. Food Chem. 2020 Apr 15;323:126808. doi: 10.1016/j.foodchem.2020.126808. [Epub ahead of print] — View Citation

Kermanshai R, McCarry BE, Rosenfeld J, Summers PS, Weretilnyk EA, Sorger GJ. Benzyl isothiocyanate is the chief or sole anthelmintic in papaya seed extracts. Phytochemistry. 2001 Jun;57(3):427-35. — View Citation

Kugo M, Keter L, Maiyo A, Kinyua J, Ndemwa P, Maina G, Otieno P, Songok EM. Fortification of Carica papaya fruit seeds to school meal snacks may aid Africa mass deworming programs: a preliminary survey. BMC Complement Altern Med. 2018 Dec 7;18(1):327. doi: 10.1186/s12906-018-2379-2. — View Citation

Okeniyi JA, Ogunlesi TA, Oyelami OA, Adeyemi LA. Effectiveness of dried Carica papaya seeds against human intestinal parasitosis: a pilot study. J Med Food. 2007 Mar;10(1):194-6. — View Citation

Sapaat A, Satrija F, Mahsol HH, Ahmad AH. Anthelmintic activity of papaya seeds on Hymenolepis diminuta infections in rats. Trop Biomed. 2012 Dec;29(4):508-12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Parasite egg count Parasitic eggs in a stool sample will be counted at the end of the intervention, using the Katz thick smear technique, and recorded as eggs per gram of faeces (EPG) 90 days after randomization
Secondary Body Mass Index for age Height, Weight and age will be collected. BMI will be calculated using WHO guidelines. 90 days after intervention
Secondary Class attendance The class register used by the class teacher to record daily student attendance will be used to gather information on attendance, enrollment, and retention of students. 90 days after randomization
Secondary Haemoglobin levels Blood sample will be taken for hemoglobin amounts at start and end of intervention 90 days after randomization
Secondary Number of children with Schistosoma mansoni Number of children with Schistosoma mansoni will be recorded at start and end of intervention 90 days after randomization
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05999825 - Sm-p80 Schistosomiasis Challenge Study Phase 2
Active, not recruiting NCT03910972 - Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Phase 1/Phase 2
Completed NCT05085470 - Repeated Controlled Human Schistosoma Mansoni Infection N/A
Completed NCT02755324 - Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding N/A
Completed NCT01054651 - A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni Phase 3
Completed NCT03893097 - Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children Phase 3
Withdrawn NCT02810613 - Leiden University Medical Center Mini Donor Bank N/A
Completed NCT02162875 - Schistosoma Mansoni in Mwanza Region, Tanzania N/A
Recruiting NCT06311344 - Filling Key Research Gaps With Clinical Implications in Mansonellosis and Schistosomiasis: a Network Approach N/A